NCT07514481 LISA vs Endotracheal Surfactant in Preterm Neonates: A Lung Ultrasound Distribution Study
| NCT ID | NCT07514481 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hamad General Hospital |
| Condition | Respiratory Distress Syndrome, Newborn |
| Study Type | INTERVENTIONAL |
| Enrollment | 22 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2026-07-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 22 participants in total. It began in 2026-01-01 with a primary completion date of 2026-07-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective, non-randomized, unblinded pilot study evaluates and compares the intrapulmonary distribution of exogenous surfactant in preterm neonates when administered via Less Invasive Surfactant Administration (LISA) versus conventional endotracheal intubation (ETT). Lung ultrasound (LUS) will be utilized to assess the pioneer Surfactant Distribution Homogeneity Index (SDHI) to quantify the evenness and extent of surfactant-induced lung aeration. Secondary objectives include evaluating changes in LUS scores, short-term clinical respiratory outcomes, and feasibility parameters for guiding future larger-scale trials.
Eligibility Criteria
Inclusion Criteria: Gestational age 24+0 to 42+6 weeks. Clinical and radiographic diagnosis of Respiratory Distress Syndrome (RDS). Requirement for surfactant within the first 3 days of life. Written informed parental consent. Exclusion Criteria: Infants intubated at birth or who received surfactant prophylactically in the delivery room. Major congenital anomalies or lung malformations (e.g., congenital diaphragmatic hernia, pulmonary hypoplasia). Syndromic or genetic conditions affecting lung or chest wall development. Severe hemodynamic instability or congenital heart disease requiring intensive support. Lack of parental consent for trial participation.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07514481 clinical trial?
This trial is open to participants of all sexes, aged 24 Weeks or older, up to 42 Weeks, studying Respiratory Distress Syndrome, Newborn. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07514481 currently recruiting?
Yes, NCT07514481 is actively recruiting participants. Contact the research team at lalkamel@hamad.qa for enrollment information.
Where is the NCT07514481 trial being conducted?
This trial is being conducted at Doha, Qatar.
Who is sponsoring the NCT07514481 clinical trial?
NCT07514481 is sponsored by Hamad General Hospital. The trial plans to enroll 22 participants.